RenovoRx Files Q2 2024 10-Q

TL;DR

RenovoRx Q2 10-Q filed. Financials updated.

AI Summary

RenovoRx, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter. Key financial data and disclosures relevant to investors are presented, including balance sheet information as of December 31, 2023, and March 31, 2024.

Why It Matters

This filing provides investors with the latest financial health and operational status of RenovoRx, Inc., crucial for understanding the company's trajectory and investment potential.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, RenovoRx faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.

Key Numbers

• 2024-06-30 — Period End Date (Indicates the end of the reporting quarter)
• 2024-08-13 — Filing Date (Date the report was submitted to the SEC)

Key Players & Entities

• RenovoRx, Inc. (company) — Filer of the 10-Q
• 20240630 (date) — End of reporting period
• 20240813 (date) — Filing date
• 2023-12-31 (date) — Balance sheet date
• 2024-03-31 (date) — Balance sheet date

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share RNXT The Nasdaq Capital M

Filing Documents

• form10-q.htm (10-Q) — 957KB
• ex31-1.htm (EX-31.1) — 10KB
• ex31-2.htm (EX-31.2) — 10KB
• ex32-1.htm (EX-32.1) — 5KB
• ex32-2.htm (EX-32.2) — 4KB
• 0001493152-24-031675.txt ( ) — 4451KB
• rnxt-20240630.xsd (EX-101.SCH) — 31KB
• rnxt-20240630_cal.xml (EX-101.CAL) — 34KB
• rnxt-20240630_def.xml (EX-101.DEF) — 125KB
• rnxt-20240630_lab.xml (EX-101.LAB) — 285KB
• rnxt-20240630_pre.xml (EX-101.PRE) — 219KB
• form10-q_htm.xml (XML) — 680KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 1

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 1 Condensed Balance Sheets as of June 30, 2024, and December 31, 2023 1 Condensed Statements of Operations for the three and six months ended June 30, 2024, and 2023 2 Condensed Statements of Convertible Preferred Stock and Stockholders' Equity for the three and six months ended June 30, 2024, and 2023 3 Condensed Statements of Cash Flows for the six months ended June 30, 2024, and 2023 5 Notes to the Unaudited Condensed Interim Financial Statements 6

: Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2: Management's Discussion and Analysis of Financial Condition and Results of Operations 15

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 26

Controls and Procedures

Item 4. Controls and Procedures 26

OTHER INFORMATION

PART II. OTHER INFORMATION 28

Legal Proceedings

Item 1. Legal Proceedings 28

Risk Factors

Item 1A. Risk Factors 28

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 29

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 29

Other Information

Item 5. Other Information 29

Exhibits

Item 6. Exhibits 30

SIGNATURES

SIGNATURES 31 Cautionary Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q, or Form 10-Q (this "Report"), particularly in the sections captioned "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," contains forward-looking 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. All statements other than present and historical facts and conditions contained in this Report, including statements regarding our future results of operations and financial position, business strategy, plans and our objectives for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "will," or "would," or the negative of these terms or other comparable terminology. Actual events or results may differ from those expressed in these forward-looking statements, and these differences may be material and adverse. Forward-looking the sufficiency of our existing cash, cash equivalents, and investments to fund our future operating expenses and capital expenditure requirements; our estimates regarding expenses, future revenue, anticipated capital requirements to fund our future operating expenses, and our need for additional financing; our financial performance; our anticipated use of our existing cash, cash equiv

View Full Filing

View this 10-Q filing on SEC EDGAR